Advanced Search
WU Weizhang, CHANG Dongshu, ZHU Fuhai, WANG Yong. Dose Distribution of Body Gamma Rays Radiotherapy for Multiple Pulmonary Metastatic Tumor[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 391-394. DOI: 10.3971/j.issn.1000-8578.2014.04.024
Citation: WU Weizhang, CHANG Dongshu, ZHU Fuhai, WANG Yong. Dose Distribution of Body Gamma Rays Radiotherapy for Multiple Pulmonary Metastatic Tumor[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 391-394. DOI: 10.3971/j.issn.1000-8578.2014.04.024

Dose Distribution of Body Gamma Rays Radiotherapy for Multiple Pulmonary Metastatic Tumor

More Information
  • Received Date: February 03, 2013
  • Revised Date: June 26, 2013
  • Objective To investigate the dose distribution of OUR-QGD whole body γ rays radiotherapy for multiple pulmonary metastatic tumor and evaluate its safety and feasibility. Methods Twenty cases of lung metastatic tumor, with 9-12 foci and diameter≤2.3 cm,were treated with OUR-QGD whole body γ rays radiotherapy. Twelve cases were supine and eight cases were prone. Gross target volume(GTV) was delineated in lung window, and 5 mm was enlarged as planning target volume (PTV).50% isodose line was around PTV and 70% isodose line was around 90% of GTV.The reference dose was defi ned as 50% isodose line with 4 Gy per fraction, and the prescribed dose was 52 Gy with 13 fractions. The dose distribution was evaluated by dose volume histogram (DVH). Results 52 Gy of body γ rays radiotherapy to 90% of GTV was equivalent to 94 Gy of conventional radiotherapy to 90% of GTV. The average dose for total lung of the supine patients was 8.36 Gy, and V20, V10 and V5 for total lung were 12.6%, 24.60% and 37.40%, respectively. The average dose for total lung of the prone patients was 8.57 Gy, and V20, V10 and V5 were 12.67%, 25.10% and 40.40%, respectively. Conclusion As to physical dosage, OUR-QGD whole body γ rays radiotherapy is safe and feasible for patients with multiple pulmonary metastatic tumor.
  • [1]
    Suit H,Skates S,Taghian A,et al.Clinical implications of heterogeneity of tumor response to radiation therapy[J].Radiother Oncol,1992, 25(4):251-60.
    [2]
    DeVita VT,Hellman S,Rosenberg SA.Cancer:principles and practice of oncology [M].5th ed.Philadelphia:Lippincott,1997: 25 2-606.
    [3]
    Okunieff P,Petersen AL,Philip A,et al.Stereotactic Body Radiation Therapy (SBRT) for lung metastases[J].Acta Oncologica,2006, 45 (7): 808-17.
    [4]
    Wu SX,Deng ML,Bao Y,et al.Therapeutic analysis of stereotactic radiotherapy for 39 patients with lung metastasis[J].Ai Zheng, 20 06,25(7): 880-4.[吴绍雄,邓美玲,包勇,等.39例肺转移瘤立体 定向放射治疗的疗效分析[J].癌症, 2006,25(7):880-4.]
    [5]
    Xiao JP,Xu GZ,Zhang HZ,et al.Stereotactic radiotherapy for pulmonary metastatic neoplasm-preliminary experience[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi,2006,15(1): 23-7.[肖 建平,徐国镇,张红志,等. 肺转移瘤立体定向放疗初探[J].中华放 射肿瘤学杂志,2006,15(1):23-7.]
    [6]
    Yu JM,Guo SF,Li JB,et al.Analysis of 30 cases with lung metastases treated by fractionated stereotactic radiotherapy[J].Lin Chuang Fei Ke Za Zhi,2002,7(1):21-3.[于金明,郭守芳,李建彬, 等.肺转移瘤体部X刀立体定向放射治疗30例分析[J].临床肺科 杂志, 2002,7(1):21-3.]
    [7]
    Xia T,Li H,Sun Q,et al.Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II nonsmall- cell lung cancer[J].Int J Radiat Oncol Biol Phys,2006, 66 (1):117-25.
    [8]
    Zheng RH,Ge D,Shi MX.Surgical treatment and prognosis of pulmonary metastasis[J].Zhonghua Jie He He Hu Xi Za Zhi,2002, 25 (4): 214-7.[郑如恒, 葛棣,石美鑫.转移性肺癌的外科治疗及预 后影响因素[J].中华结核和呼吸杂志,2002, 25(4): 214-7.]
  • Related Articles

    [1]CHEN Lijun, CHEN Jingqi, ZENG Bohang. Correlation of CD68+ Tumor-associated Macrophages Number with Ki-67 Expression and Prognosis of Patients with Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 774-778. DOI: 10.3971/j.issn.1000-8578.2016.09.009
    [2]LI Wen, FENG Yanlin. Valuation of SUVmax, Ki-67, p53 and EGFR in Predicting Effect of Neoadjuvant Chemotherapy on Triple-negative Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(1): 45-47. DOI: 10.3971/j.issn.1000-8578.2016.01.010
    [3]YAN Su, LI Bin, MA Xuxiang, MA Yingcai, XIONG Yuanzhi, GUO Xinjian, MA Yubin, YU Pengjie, WU Junqi, XIE Dawei, ZHAO Junhui, WU Huixian. Clinicopathological Characteristics of Young Gastric Cancer Patients in Hehuang Valley[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 502-505. DOI: 10.3971/j.issn.1000-8578.2015.05.018
    [4]ZHANG Cui-cui, WANG Jing, LI Kai. Characteristics and Prognostic Analysis of 60 Young Patients with Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 274-277. DOI: 10.3971/j.issn.1000-8578.2011.03.009
    [5]LIANG Xu-dong, SHI Xiao-feng, JIA Zong-qi. Detection andSignificance of PTEN, NFκB andKi-67 in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 326-629. DOI: 10.3971/j.issn.1000-8578.2010.03.023
    [6]ZHONG Wei-ming, MA Li-ping, CAI Yong-lin, LIANG Wei, CHEN Wan-sheng, HUANG Zhuo, YU Hong, TAN Bi-fang. Relationship between Expression of Ki-67 Protein and Radiosensitivity of Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 195-196. DOI: 10.3971/j.issn.1000-8578.2010.02.019
    [7]SHI Guo-qing, ZHAO Kui, WANG Hong, LIU Mo-rong. Expression of Gastrin and Ki-67 in Gastric Cancer and Precancerous Pesions[J]. Cancer Research on Prevention and Treatment, 2009, 36(09): 756-758. DOI: 10.3971/j.issn.1000-8578.2009.09.011
    [8]HE Yan-jiao, LIU Zhao-xia, LI Hong-li, YU Jin, LI Guang. Expression and Significance of E-cadherin and Ki-67 in Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2007, 34(09): 699-702. DOI: 10.3971/j.issn.1000-8578.2529
    [9]ZHENG Lei, HAN Yue-wu. Antisense Oligodeoxyribonucleotide Target Ki-67 Inhibits Proliferation of Human Hepatocellucar Carcinoma Cell HEPG-7402 in Vitro[J]. Cancer Research on Prevention and Treatment, 2006, 33(12): 862-864. DOI: 10.3971/j.issn.1000-8578.354
    [10]DENG Jie, CAO Dun-wen, LIU Ming-qiu, ZHU Run-qing, CHEN Hong-lei, CHEN Dao-ying, WANG Ji-e. Expression of p73, PTEN and Ki-67 Proteins in Endometrioid Adenocarcinoma and Their Significance[J]. Cancer Research on Prevention and Treatment, 2006, 33(11): 811-813. DOI: 10.3971/j.issn.1000-8578.374

Catalog

    Article views (1270) PDF downloads (858) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return